Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Journal Mobile Options
Table of Contents
Vol. 60, No. 6, 1994
Issue release date: 1994
Section title: Clinical Neuroendocrinology
Neuroendocrinology 1994;60:626–634
(DOI:10.1159/000126806)

Decreased Delta-Sleep and Plasma Delta-Sleep-Inducing Peptide in Patients with Cushing Syndrome

Friedman T.C.a,b · García-Borreguero D.c · Hardwick D.b · Akuete C.N.b · Doppman J.L.e · Dorn L.D.b,d,f · Barker C.N.c · Yanovski J.A.b · Chrousos G.P.b
aLaboratory of Developmental Neurobiology, and bDevelopmental Endocrinology Branch, NICHD, cClinical Psychobiology Branch, and dClinical Neuroendocrinology Branch, NIMH, eDiagnostic Radiology Department, Clinical Center, National Institutes of Health, Bethesda, Md., fSchool of Nursing, University of Pittsburgh, Pittsburgh, Pa., USA

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00
EUR 35.00
USD 39.00

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates



Select

The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Neuroendocrinology

Received: April 28, 1994
Accepted: July 19, 1994
Published online: April 09, 2008
Issue release date: 1994

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN

Abstract

To evaluate the sleep disturbances of patients with Cushing syndrome and to examine the relationship between the sleep disturbances and plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI), we performed three polysomnographic/endocrinological studies in patients with Cushing syndrome. In study 1, polysomnography was studied in 12 patients and 12 matched normal volunteers. In addition, DSIP-LI was measured every 30 min for 24 h in 9 patients with Cushing syndrome and 12 normal volunteers. The percentage of time spent in delta sleep (stages 3 and 4) was significantly reduced in patients with Cushing syndrome (5.8 ± 1.4%; mean ± SEM) compared to normal volunteers (14.0 ± 2.5%) (p < 0.01). REM sleep indices, however, were not significantly different between the two groups. There was a significant negative correlation between amount of delta sleep and 08.00 h DSIP-LI (r = –0.43, p < 0.05), which is against the notion of a causal relationship between DSIP-LI and delta sleep. The circadian rhythm of plasma DSIP-LI was found to be similar in Cushing patients and normal volunteers. In study 2, we measured plasma levels of delta-sleep-inducing peptide-like immunoreactivity (DSIP-LI) at 08.00 h in 65 patients with Cushing syndrome and 49 normal volunteers. The 08.00 h DSIP-LI concentrations of 797 ± 57 pmol/l (mean ± SEM) in the patients with Cushing syndrome were significantly reduced compared to the level of 1,062 ± 99 pmol/l found in the normal volunteers (p < 0.05). In study 3, plasma was drawn simultaneously from the petrosal sinuses and peripheral veins of Cushing patients. No central-to-peripheral gradient for plasma DSIP-LI was noted and neither peripheral, nor central plasma DSIP-LI was affected by administration of intravenous ovine CRH. We conclude that patients with Cushing syndrome have less delta sleep and lower plasma concentrations of DSIP-LI than normal controls, however a causal relationship between the two appears to be unlikely. The pituitary does not appear to be the site of synthesis of plasma DSIP, whose source remains unknown.

© 1994 S. Karger AG, Basel


Article / Publication Details

First-Page Preview
Abstract of Clinical Neuroendocrinology

Received: April 28, 1994
Accepted: July 19, 1994
Published online: April 09, 2008
Issue release date: 1994

Number of Print Pages: 9
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: http://www.karger.com/NEN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.